Dr Reddy’s to launch generic Gleevec in US

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).

The Gleevec brand and generic had U.S. sales of approximately $868 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.

Dr. Reddy’s Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.

Gleevec is a trademark of Novartis Pharmaceuticals Corporation.

https://www.marketscreener.com/DR-REDDY-S-LABORATORIES-9058869/news/Dr-Reddy-Laboratories-Announces-the-Launch-of-Imatinib-Mesylate-Tablets-USP-in-the-U-S-Market-27347090/